• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

四个国家药典中药品信息的比较。

A comparison of drug product information in four national compendia.

作者信息

Alloza J L, Lasagna L

出版信息

Clin Pharmacol Ther. 1983 Mar;33(3):269-77. doi: 10.1038/clpt.1983.32.

DOI:10.1038/clpt.1983.32
PMID:6825384
Abstract

Four widely used compendia of prescribing information have been received to examine the way in which some drug companies recommend uses for several anti-inflammatory products and describe the major dangers in their use. The Physician's Desk Reference (PDR) cites the greatest absolute number of indications for steroids with systemic action, as well as the greatest number of contraindications, warnings and precautions, and adverse effects. The total number of precautions appearing in the PDR is three times the mean for the other compendia, and the number of adverse effects is four times the mean of the others. Together, these other compendia contain 70.5% of the number of words in the PDR. The PDR contains statements that are strongly directive for the physician and that do not appear in the other compendia. Regulatory and social differences may at least partially explain these discrepancies.

摘要

已收到四份广泛使用的处方信息汇编,以研究一些制药公司推荐几种抗炎产品用途的方式,并描述其使用中的主要风险。《医师案头参考》(PDR)列出了具有全身作用的类固醇的绝对适应症数量最多,以及禁忌症、警告和注意事项以及不良反应的数量最多。PDR中出现的注意事项总数是其他汇编平均值的三倍,不良反应数量是其他汇编平均值的四倍。这些其他汇编总共包含PDR字数的70.5%。PDR包含对医生有强烈指导作用且未出现在其他汇编中的陈述。监管和社会差异可能至少部分解释了这些差异。

相似文献

1
A comparison of drug product information in four national compendia.四个国家药典中药品信息的比较。
Clin Pharmacol Ther. 1983 Mar;33(3):269-77. doi: 10.1038/clpt.1983.32.
2
A Collaborative Assessment Among 11 Pharmaceutical Companies of Misinformation in Commonly Used Online Drug Information Compendia.11家制药公司对常用在线药品信息汇编中的错误信息进行的联合评估。
Ann Pharmacother. 2016 May;50(5):352-9. doi: 10.1177/1060028016635196. Epub 2016 Feb 25.
3
Comparison of potentially hepatotoxic drugs among major US drug compendia.美国主要药品药典中潜在肝毒性药物的比较。
Res Social Adm Pharm. 2005 Sep;1(3):460-79. doi: 10.1016/j.sapharm.2005.06.005.
4
Lack of drug interaction conformity in commonly used drug compendia for selected at-risk dermatologic drugs.常用药物手册中选定的高危皮肤科药物缺乏药物相互作用一致性。
Am J Clin Dermatol. 2005;6(2):105-11. doi: 10.2165/00128071-200506020-00005.
5
Dose discrepancies between the Physicians' Desk Reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug events.《医师案头参考》与医学文献之间的剂量差异及其在与剂量相关的药物不良事件高发率中可能发挥的作用。
Arch Intern Med. 2001 Apr 9;161(7):957-64. doi: 10.1001/archinte.161.7.957.
6
Caveat emptor: Erroneous safety information about opioids in online drug-information compendia.买家需谨慎:在线药品信息汇编中关于阿片类药物的错误安全信息。
J Opioid Manag. 2016 Jul-Aug;12(4):281-8. doi: 10.5055/jom.2016.0343.
7
Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications.药品手册中支持典型和非典型抗精神病药物超说明书用药的证据质量。
Int J Risk Saf Med. 2012 Jan 1;24(3):137-46. doi: 10.3233/JRS-2012-0567.
8
Comparative assessment of four drug interaction compendia.四种药物相互作用汇编的比较评估
Br J Clin Pharmacol. 2007 Jun;63(6):709-14. doi: 10.1111/j.1365-2125.2006.02809.x. Epub 2006 Dec 7.
9
Antineoplastic agents: comparing off-label uses among authoritative drug compendia.抗肿瘤药物:比较权威药物汇编中的超说明书用药情况。
Hosp Formul. 1993 Jul;28(7):641-2, 647.
10
Implementing a Process to Review Product-Specific Misinformation in Online Drug Information Compendia.实施一个流程以审查在线药品信息汇编中特定产品的错误信息。
Ther Innov Regul Sci. 2015 Mar;49(2):262-268. doi: 10.1177/2168479014558274.

引用本文的文献

1
Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems.
Front Drug Saf Regul. 2024 Jan 26;3:1323057. doi: 10.3389/fdsfr.2023.1323057. eCollection 2023.
2
Discrepancies in listed adverse drug reactions in pharmaceutical product information supplied by the regulatory authorities in Denmark and the USA.丹麦和美国监管机构提供的药品产品信息中列出的不良反应差异。
Pharmacol Res Perspect. 2014 Jun;2(3):e00038. doi: 10.1002/prp2.38. Epub 2014 Apr 22.
3
Social pharmacology: expanding horizons.社会药理学:拓展视野。
Indian J Pharmacol. 2014 May-Jun;46(3):246-50. doi: 10.4103/0253-7613.132151.
4
Contraindication labelling changes in the United States and Germany.美国和德国的禁忌标识变更。
Eur J Clin Pharmacol. 2007 Jan;63(1):87-93. doi: 10.1007/s00228-006-0229-5. Epub 2006 Nov 24.
5
Psychoactive drug advertising: a comparison of technical information from three countries: Brazil, United States and United Kingdom.精神活性药物广告:巴西、美国和英国三个国家的技术信息比较。
Sao Paulo Med J. 2005 Sep 1;123(5):209-14. doi: 10.1590/s1516-31802005000500002. Epub 2005 Dec 8.
6
Development of new drugs in man: a review.人体新药研发综述
J R Soc Med. 1986 Feb;79(2):96-9. doi: 10.1177/014107688607900210.